Micro and nanoparticle-based delivery systems for vaccine immunotherapy: an immunological and materials perspective
- PMID: 23225517
- DOI: 10.1002/adhm.201200268
Micro and nanoparticle-based delivery systems for vaccine immunotherapy: an immunological and materials perspective
Abstract
The development and widespread application of vaccines has been one of the most significant achievements of modern medicine. Vaccines have not only been instrumental in controlling and even eliminating life-threatening diseases like polio, measles, diphtheria, etc., but have also been immensely powerful in enhancing the worldwide outlook of public health over the past century. Despite these successes, there are still many complex disorders (e.g., cancer, HIV, and other emerging infectious diseases) for which effective preventative or therapeutic vaccines have been difficult to develop. This failure can be attributed primarily to our inability to precisely control and modulate the highly complex immune memory response, specifically the cellular response. Dominated by B and T cell maturation and function, the cellular response is primarily initiated by potent immunostimulators and antigens. Efficient and targeted delivery of these immunomodulatory and immunostimulatory molecules to appropriate cells is key to successful development of next generation vaccine formulations. Over the past decade, particulate carriers have emerged as an attractive means for enhancing the delivery efficacy and potency of vaccines and associated immunomodulatory molecules. Specifically, polymer-based micro and nanoparticles are being extensively studied for a wide variety of applications. In this review, we discuss the immunological fundamentals for developing effective vaccines and how materials and material properties can be exploited to improve these therapies. Particular emphasis is given to polymer-based particles and how the route of administration of particulate systems affects the phenotype and robustness of an immune response. Comparison of various strategies and recent advancements in the field are discussed along with insights into current limitations and future directions.
Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Similar articles
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
Engineering vaccines and niches for immune modulation.Acta Biomater. 2014 Apr;10(4):1728-40. doi: 10.1016/j.actbio.2013.12.036. Epub 2013 Dec 27. Acta Biomater. 2014. PMID: 24373907 Review.
-
Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.Haematologica. 2002 Sep;87(9):989-1001. Haematologica. 2002. PMID: 12217812 Review.
-
Nano- and micro-encapsulated systems for enhancing the delivery of resveratrol.Ann N Y Acad Sci. 2013 Jul;1290:107-12. doi: 10.1111/nyas.12130. Ann N Y Acad Sci. 2013. PMID: 23855472 Review.
-
Targeting nanoparticles to dendritic cells for immunotherapy.Methods Enzymol. 2012;509:143-63. doi: 10.1016/B978-0-12-391858-1.00008-3. Methods Enzymol. 2012. PMID: 22568905 Review.
Cited by
-
Recent advances of biomaterials in biotherapy.Regen Biomater. 2016 Jun;3(2):99-105. doi: 10.1093/rb/rbw007. Epub 2016 Mar 5. Regen Biomater. 2016. PMID: 27047675 Free PMC article. Review.
-
Design of virus-based nanomaterials for medicine, biotechnology, and energy.Chem Soc Rev. 2016 Jul 25;45(15):4074-126. doi: 10.1039/c5cs00287g. Chem Soc Rev. 2016. PMID: 27152673 Free PMC article. Review.
-
Evolution of Vaccines Formulation to Tackle the Challenge of Anti-Microbial Resistant Pathogens.Int J Mol Sci. 2023 Jul 27;24(15):12054. doi: 10.3390/ijms241512054. Int J Mol Sci. 2023. PMID: 37569427 Free PMC article. Review.
-
Engineering self-assembled materials to study and direct immune function.Adv Drug Deliv Rev. 2017 May 15;114:60-78. doi: 10.1016/j.addr.2017.03.005. Epub 2017 Apr 6. Adv Drug Deliv Rev. 2017. PMID: 28392305 Free PMC article. Review.
-
Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.mSphere. 2020 Dec 2;5(6):e00901-20. doi: 10.1128/mSphere.00901-20. mSphere. 2020. PMID: 33268566 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous